# 英國製藥集團 GSK 正在洽談以超過 90 億美元收購癌症藥物製造商 Nuvalent，《金融時報》報導。

*biotech · news · 2026-06-09 · The Hindu Business Line*

## Key points

- GSK 正在進行收購 Nuvalent 超過 90 億美元的高階談判。
- 潛在的收購交易最早可能於本週完成。
- Nuvalent 目前市值約為 70 億美元，明顯低於提議的收購價格。
- 此收購將促成預計 2026 年生物製藥併購交易的創紀錄激增。

UK pharmaceutical group GSK is ‌in talks to buy cancer drugmaker ​Nuvalent for more than $9 billion, ⁠the Financial Times reported on Monday, citing people familiar with the matter. Here ‌are some details: * The companies were locked in ‌discussions late on Monday, aiming ‌to ⁠agree on a deal ⁠as soon as this week, the report said. * A potential deal could ​value Nuvalent ‌between $9 billion and $10 billion, according to the report. * Reuters could not immediately verify the report. ‌Nuvalent and GSK did not ​immediately respond to Reuters requests for comment. * Nuvalent has a ⁠market value of nearly $7 billion, according to LSEG data. * Nuvalent ‌is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, according to its website. * The deal comes at a time ‌of biotech dealmaking frenzy, with large drugmakers ​on a spending spree to expand their product pipelines ⁠this year. If the current ⁠pace holds, the total biopharma M&A value could exceed $250 billion ‌in 2026, according to a Stifel note in April. Published on June 9, 2026

**Companies:** GSK, Nuvalent
**Countries:** UK

[Read the full story on The Hindu Business Line](https://www.thehindubusinessline.com/companies/gsk-in-talks-to-buy-cancer-biotech-nuvalent-for-more-than-9-billion/article71079129.ece)

---

Canonical: https://newsio.io/zh-TW/n/097559b8-157b-4322-8d31-f73db8ead532/gsk-90-nuvalent
Summarized by Newsio from The Hindu Business Line. https://newsio.io/how-it-works